Sep 1, 2025
👏👏 We’re excited to announce that Dr. Sophie Lin has joined H7 BioCapital as our new Partner! She will lead global Business Development, Licensing & Strategic Partnership in the pharmaceutical industry, strengthening our mission to advance life science investment and build impactful healthcare partnerships globally.
About Dr. Sophie Lin
Sophie is an experienced business development leader with a Ph.D. in Molecular and Cellular Biology, combining deep scientific expertise with a proven track record in building strategic partnerships.
Out-Licensing Excellence:
• Sophie has successfully led multiple international out-licensing deals with partners including Eli Lilly, ArriVent Biopharma, and others, generating over $300 million in upfront payments and potential milestones exceeding $4 billion. She has also played a key role in a major deal with Merck KGaA.
In-Licensing Leadership:
• Sophie has driven 10+ in-licensing projects across various therapeutic areas, contributing to significant potential market share in the Asian healthcare sector.
Research & Development Expertise:
• With nearly 20 years of experience in biology research, drug discovery, IND-enabling studies, regulatory strategies, and early clinical development, Sophie has delivered multiple clinical candidates in oncology and metabolic diseases.
Academic Contributions:
• Sophie has authored 40+ scientific publications, book chapters, and patents in basic and translational research and drug development.
Looking Ahead
We warmly welcome Dr. Sophie Lin to the team and thank her for joining us. If you are a therapeutics company with innovative pipelines or licensing-out opportunities, we would love to explore potential collaborations with H7 BioCapital.